Statpedia’s Post

Using PGA to identify potent and selective drugs for the treatment of cancer Across the world, cancer poses serious threats to everyone’s health, and overall quality of life. In order to identify potential effective drugs for new therapeutics, the research team at OncoDxRx leveraged its proprietary gene expression-driven drug identification platform, PGA, to facilitate clinical decision-making on three types of cancers, including lung, pancreatic, and breast cancer. Using cell-free mRNA based gene expression signature strategies and applying rigorous filters for similarity and selectivity, OncoDxRx scientists identified an array of existing drugs which the patient is likely to respond to. This knowledge provided clinical guidance for treatment strategy optimization, leading to better patient outcome. The innovative PGA test has not only presented a breakthrough for effective drug identification but has also led to the revolution of drug repurposing. PGA expands OncoDxRx’s one-of-a-kind liquid biopsy pipelines and paves the way toward a safer, more effective therapeutic future for patients battling lung, pancreatic, and breast cancers. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

Exploring the Booming $42.0 Billion Cancer Biomarkers Market 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲: https://lnkd.in/d2AzRpZZ The size of global #cancerbiomarkers market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by 2029, growing at a CAGR of 11.3% from 2024 to 2029. BioAgilytix Bill & Melinda Gates Medical Research Institute Owkin Quanterix Scipher Medicine Metabolon, Inc. Kura Oncology, Inc. InsideTracker Advanced Cell Diagnostics Biodesix, Inc. Eurofins Central Laboratory Koneksa Biocare Medical Clinical ink Denali Therapeutics Biofourmis KCAS Bio Exosome Diagnostics Drug Discovery News Biological Dynamics Nucleai BostonGene AbleTo Inc. MESO SCALE DIAGNOSTICS, LLC. Alto Neuroscience Mitsubishi Tanabe Pharma America AiCure Paige Amador Bioscience Geneoscopy CorDx HALO Precision Diagnostics Aster Insights RareCyte, Inc. Sanguine HiFiBiO Therapeutics Active Motif InterVenn Biosciences Ethos Laboratories Flagship Biosciences, Inc.

Write a report on the Global Cancer Biomarker Market forecast for 2022-2028, detailing the market size, projected growth, and key drivers of growth. Cancer Biomarker Market Size, Share & Trends Analysis Report By Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetics-based Tests), By Biomolecule (Genetic Biomarkers, Protein Biomarkers, Glyco-biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others), By Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Others), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. 𝐈𝐌𝐈𝐑 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 #Note: The above outline provides a general structure for the content. You may modify and expand it based on the specific requirements and available information.   📚𝐆𝐞𝐭 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐀𝐭 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐏𝐫𝐢𝐜𝐞:📝👇https://lnkd.in/d-RrCZsg 📚𝐑𝐞𝐩𝐨𝐫𝐭 𝐅𝐨𝐜𝐮𝐬𝐞𝐝 𝐎𝐧 𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬:👇 Abbott Agilent Technologies bioMérieux Specific Diagnostics (now part of bioMérieux) Bio-Rad Laboratories Bristol Myers Squibb Bristol Myers Squibb UK & Ireland Bristol-Myers Squibb Exact Sciences GE HealthCare Hologic, Inc. Hologic (Formerly Gen-Probe) Hologic Costa Rica Illumina Merck Group QIAGEN Merck Life Science Merck KGaA, Darmstadt, Germany Merck Healthcare PerkinElmer QIAGEN Wrocław Siemens Healthineers Quest Diagnostics Quest Diagnostics Employer Solutions Roche Diagnostics India, Neighbouring Markets Roche Thermo Fisher Scientific

Biotechnology Transformations and the Rise of Immunology: The biotechnology sector is witnessing rapid shifts in investment trends, with immunology emerging as a key focus. In 2023, investment in oncology declined while interest in immunotherapies and immune-related innovations surged. However, 2024 is seeing a resurgence in oncology investments, driven by advancements in personalized medicine, immunotherapies, and regulatory support. Meanwhile, immunology continues to attract strong venture capital, fueled by technological breakthroughs like CRISPR and CAR-T therapies. As the biotech landscape evolves, companies in both fields must embrace innovation, leverage strategic partnerships, and adapt to new opportunities for sustained growth. #biotechnology #immunology #oncology #investment #innovation #biopharma #venturecapital #growth https://lnkd.in/dk9Kvy-8 #Nabil_Alhakamy

🔍 Exciting news in biotech investments! These investments show the growing potential in biometrics. Great to see advancements across different health areas, from mental health to cancer treatment 🇺🇸 Spyre Therapeutics | $180 million PIPE | monoclonal antibodies | preclinical in inflammatory bowel disease 🇺🇸 Engrail Therapeutics | $157 million series B | precision neuroscience | phase 2 in generalized anxiety disorder 🇨🇦 Cybin Inc | $150 million PIPE | mental healthcare | phase 2 in major depressive disorder 🇩🇪 Tubulis GmbH | €128 million ($138.75 million) series B2 | antibody drug conjugates | preclinical in multiple solid tumors 🇺🇸 Unicycive Therapeutics | $50 million PIPE | kidney disease treatments | phase 1 in hyperphosphatemia 🇬🇧 Relation | $35 million seed | multi omics for drug discovery | discovery in osteoporosis 🇸🇪 Asgard Therapeutics | €30 million ($32.53 million) series A | cancer immunotherapies | preclinical in cancer 🇬🇧 Mission Therapeutics | £25.2 million ($32 million) | deubiquitylating enzyme inhibitors | phase 2 in cardiac surgery-associated kidney injury 🇺🇸 Elicio Therapeutics | $6 million PIPE | immunotherapies | phase 2 in pancreatic ductal adenocarcinoma

The Hepatocyte Growth Factor market is evolving with significant advancements and key players making waves. Here's a quick overview: 🔬 ViroMed: A leader in HGF research, ViroMed is driving innovations with their cutting-edge gene therapies to address liver diseases. #ViroMed #GeneTherapy 🧬 AnGes MG: Known for its pioneering work in gene delivery systems, AnGes MG is leveraging HGF for regenerative medicine and improving patient outcomes. #AnGesMG #RegenerativeMedicine 🌟 M3 Biotechnology: M3 Biotechnology is at the forefront of developing novel HGF-based treatments aimed at neurodegenerative diseases. #M3Biotechnology #NeurodegenerativeDiseases 💊 AVEO Pharmaceuticals: AVEO is exploring HGF’s potential in oncology, focusing on targeted therapies that enhance cancer treatment efficacy. #AVEOPharmaceuticals #Oncology 🔬 Molecular Partners: With their proprietary DARPins technology, Molecular Partners is innovating HGF therapies for various therapeutic areas. #MolecularPartners #DARPins 🧪 Yooyoung Pharm: Yooyoung Pharm is making strides in HGF research with a focus on new drug development and therapeutic applications. #YooyoungPharm #DrugDevelopment 🔬 F-star: F-star’s commitment to HGF research includes developing bispecific antibodies that could revolutionize cancer therapy. #Fstar #CancerTherapy 🧬 Galaxy Biotech: Galaxy Biotech is working on advanced HGF solutions that aim to improve liver health and regenerative capabilities. #GalaxyBiotech #LiverHealth 🔬 Kringle Pharma: Kringle Pharma’s innovative approach involves utilizing HGF for novel treatments in liver and kidney diseases. #KringlePharma #LiverDiseases Stay tuned for more updates and insights into the HGF market! #HealthcareInnovation #Biotech #Pharmaceuticals #RegenerativeMedicine #GeneTherapy #CancerResearch #LiverHealth #DrugDevelopment #Oncology #Biotechnology #PharmaNews #MedicalResearch #Therapeutics #HGF #BiotechTrends Read Report @ https://lnkd.in/gvkZXbBb

🤝 We're proud of the collaboration between Genialis and Swiss biopharma company Debiopharm. 🔬 Genialis’s proprietary ResponderID™ framework is being used to develop predictive biomarkers for DNA Damage Response (DDR) and to facilitate the development of targeted oncology drugs in a truly scalable and AI-driven way. 📈 Their recent $13M Series A funding in 2023 provided a key boost for their growth and the expansion of the ResponderID™ platform. 💡 Redalpine's Michael and Agnieszka continue to #empowerGameChangers and support Genialis as it becomes a leading force in the fight against cancer. 👏 Miha Stajdohar, Tjaša Krisper - Kutin - Kutin, Rafael Rosengarten and Luka Ausec #biotech #VC #oncology #empoweringGameChangers

Pan-#Cancer #Proteogenomics Expands the Landscape of #Drug Targets | Phenomenal OPEN ACCESS Resource from Bing Zhang & Co. | Now Breaking Online at Cell Press 👏 | #DrugDevelopment #Repurposing #Diagnostics | Fewer than 200 proteins are targeted by cancer drugs approved by the Food and Drug Administration (FDA). Here* Sara Savage, Xinpei Yi, Jonathan Lei, et al integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) proteogenomics data from 1,043 patients across 10 cancer types with additional public datasets to identify potential therapeutic targets. Pan-cancer analysis of 2,863 druggable proteins reveals a wide abundance range and identifies biological factors that affect mRNA-protein correlation. Integration of proteomic data from tumors and genetic screen data from cell lines identifies protein overexpression- or hyperactivation-driven druggable dependencies, enabling accurate predictions of effective drug targets. Proteogenomic identification of synthetic lethality provides a strategy to target tumor suppressor gene loss. Combining proteogenomic analysis and MHC binding prediction prioritizes mutant KRAS peptides as promising public neoantigens. Computational identification of shared tumor-associated antigens followed by experimental confirmation nominates peptides as immunotherapy targets. These analyses, summarized at https://lnkd.in/eGu4CwnJ, form a comprehensive landscape of protein and peptide targets for companion diagnostics, drug repurposing, and therapy development. *https://lnkd.in/e75qsaxd Celentyx Ltd Professor Nicholas Barnes PhD, FBPhS Catherine Brady Omar Qureshi GRAPHICAL ABSTRACT

🚀 Exciting News from Maximize Market Research Pvt. Ltd! 🚀 🌟 PDX Model Market Set for Remarkable Growth! 🌟 Our latest research reveals that the PDX Model Market size, valued at USD 177.32 Mn in 2022, is expected to skyrocket to nearly USD 438.29 Mn by 2029, boasting an impressive CAGR of 13.8%! Sample Report Link :https://lnkd.in/dWYhC7KP PDX Model Market Overview: Patient-Derived Xenograft (PDX) models are gaining traction as the gold standard for preclinical therapeutic models due to their relevance and predictive accuracy. These models are pivotal in personalizing cancer treatment, ensuring tailored therapies for patients. Market Dynamics: Rising Demand for Personalized Medicine: With an increase in R&D efforts and substantial support from the public and private sectors, the demand for PDX models is soaring. Innovative Research Applications: PDX models are now integral to pharmacology, biomarker, and pharmacokinetics studies, enhancing the discovery and development of new cancer therapies. Overcoming Challenges: While high costs and complex modeling remain challenges, the growing adoption of humanized PDX models is set to revolutionize the market. Regional Insights: North America Leads the Way: With robust funding and a high focus on cancer research, North America dominated the PDX Model Market in 2022. Europe and Beyond: Europe is also making significant strides, with large-scale PDX libraries supporting drug development and biomarker screening. PDX Model Market Key Players 1. JSR Corporation 2. WuXi AppTec 3. Champions Oncology, Inc. 4. THE JACKSON LABORATORY 5. Charles River Laboratories #PDXModel #CancerResearch #España #Eurocopa #Argentina #Palmer  #PersonalizedMedicine #MarketGrowth #HealthcareInnovation